Acceleron Pharma’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
5/10/2013 7:46:01 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, today announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on Myelodysplastic Syndromes in Berlin, Germany.
Help employers find you! Check out all the jobs and post your resume.
comments powered by